Cummins Strategy Partners
Strategic advisors to Pharma and Biotech for EU commercialisation
The Path to Commercialisation
Strategy & Market Entry
Pre Launch and Market assessment
-
Evaluate EU market attractiveness
-
Map regulatory and access pathways (EMA vs national)
-
Identify early-access opportunities and potential for chargeable supply
De-risks entry and prioritizes markets for focused investment
Early Access Enablement
-
Design and manage Early Access / Named Patient Programmes (EAP, CUP,NPP)
-
Secure regulatory, ethical and pricing compliance
-
Partner with local distributors as required
Accelerates time to first patient and builds real-world data pre-approval
Evidence & Launch Optimisation
Commercial Entry Planning
-
Develop go-to-market plan (direct vs partner model)
-
Conduct partner/distributor identification due diligence
-
Support selection of pharmacovigilance, logistics, and medical partners
Provides low-risk, scalable route to EU commercialization
Real World Evidence Generation
-
Build data capture frameworks during EAPs
-
Liaise with payers, HTA bodies, and KOLs to align data generation with future pricing needs
Supports reimbursement negotiations and value demonstration
Launch & Post launch Support
Launch Execution Support
-
Coordinate affiliate setup, exploitent services, pricing & reimbursement submissions
-
Manage distribution, patient support, and medical information programmes
Seamless transition from early access to full commercial supply
Post Launch Optimisation
-
Monitor pricing, access performance, and patient uptake
-
Advise on life cycle management, label expansion, or other post approval needs
Sustain market access and optimise long term value